Sang Lee

Dr. Sang Lee

Penn State Health Hershey Medical Center

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Genes & Diseases
Verified
Journal Article
Open access
SLSang Lee
Sang Lee
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.

19 February 2009 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
RMRyan M Mitchell
Ryan M Mitchell
SLSang Lee
Sang Lee
WRWilliam T Randazzo
William T Randazzo
ZSZachary Simmons
Zachary Simmons
JCJames Connor
James Connor
Background: Polymorphisms in the MHC class 1-like gene known as HFE have been proposed as genetic modifiers of neurodegenerative diseases that include neuroinflammation as part of the disease process. Variants of HFE are relatively common in the general population and are most commonly associated with iron overload, but can promote subclinical cellular iron loading even in the absence of clinically identified disease. The effects of the variants as well as the resulting cellular iron dyshomeostasis potentially impact a number of disease-associated pathways. We tested the hypothesis that the two most common HFE variants, H63D and C282Y, would affect cellular secretion of cytokines and trophic factors. Methods: We screened a panel of cytokines and trophic factors using a multiplexed immunoassay in human neuroblastoma SH-SY5Y cells expressing different variants of HFE. The influence of cellular iron secretion on the potent chemokine monocyte chemoattractant protein-1 (MCP-1) was assessed using ferric ammonium citrate and the iron chelator, desferroxamine. Additionally, an antioxidant, Trolox, and an anti-inflammatory, minocycline, were tested for their effects on MCP-1 secretion in the presence of HFE variants. Results: Expression of the HFE variants altered the labile iron pool in SH-SY5Y cells. Of the panel of cytokines and trophic factors analyzed, only the release of MCP-1 was affected by the HFE variants. We further examined the relationship between iron and MCP-1 and found MCP-1 secretion tightly associated with intracellular iron status. A potential direct effect of HFE is considered because, despite having similar levels of intracellular iron, the association between HFE genotype and MCP-1 expression was different for the H63D and C282Y HFE variants. Moreover, HFE genotype was a factor in the effect of minocycline, a multifaceted antibiotic used in treating a number of neurologic conditions associated with inflammation, on MCP-1 secretion. Conclusion: Our results demonstrate that HFE polymorphisms influence the synthesis and release of MCP-1. The mechanism of action involves cellular iron status but it appears there could be additional influences such as ER stress. Finally, these data demonstrate a pharmacogenetic effect of HFE polymorphisms on the ability of minocycline to inhibit MCP-1 secretion.

28 December 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SLSang Lee
Sang Lee
SLSiying Liu
Siying Liu
RMRyan M. Mitchell
Ryan M. Mitchell
BSBecky Slagle‐Webb
Becky Slagle‐Webb
YHYoung‐Soo Hong
Young‐Soo Hong
JCJames R. Connor
James R. Connor
HFE is a protein that impacts cellular iron uptake. HFE gene variants are identified as risk factors or modifiers for multiple diseases. Using HFE stably transfected human neuroblastoma cells, we found that cells carrying the C282Y HFE variant do not differentiate when exposed to retinoic acid. Therefore, we hypothesized HFE variants would impact response to therapeutic agents. Both the human neuroblastoma and glioma cells that express the C282Y HFE variant are resistant to Temodar, geldanamycin and γ‐radiation. A gene array analysis revealed that p16INK4A (p16) expression was increased in association with C282Y expression. Decreasing p16 protein by siRNA resulted in increased vulnerability to all of the therapeutic agents suggesting that p16 is responsible for the resistance. Decreasing HFE expression by siRNA resulted in a 85% decrease in p16 expression in the neuroblastoma cells but not the astrocytoma cells. These data suggest a potential direct relationship between HFE and p16 that may be cell specific or mediated by different pathways in the different cell types. In conclusion, the C282Y HFE variant impacts the vulnerability of cancer cells to current treatment strategies apparently by increasing expression of p16. Although best known as a tumor suppressor, there are multiple reports that p16 is elevated in some forms of cancer. Given the frequency of the HFE gene variants, as high as 10% of the Caucasian population, these data provide compelling evidence that the C282Y HFE variant should be part of a pharmacogenetic strategy for evaluating treatment efficacy in cancer cells.

16 June 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CJChunhui Jiang
Chunhui Jiang
RMRenée M. McKay
Renée M. McKay
SLSang Lee
Sang Lee
CRCarlos Guillermo Romo
Carlos Guillermo Romo
JBJaishri O. Blakeley
Jaishri O. Blakeley
LLLu Q. Le
Lu Q. Le

1 September 2012 in Bone
Verified
Journal Article
Closed access
Byung-Hyun ParkByung-Hyun Park
Byung-Hyun Park
LZLu Zhou
Lu Zhou
Kyu JangKyu Jang
Kyu Jang
HPHo Sung Park
Ho Sung Park
JLJung Min Lim
Jung Min Lim
JKJung Ryul Kim
Jung Ryul Kim

8 June 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ILIna Ly
Ina Ly
CRCarlos Guillermo Romo
Carlos Guillermo Romo
SGSally Gottesman
Sally Gottesman
KKKristen M. Kelly
Kristen M. Kelly
DKDeanna Kornacki
Deanna Kornacki
PWPierre Wolkenstein
Pierre Wolkenstein